Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low during trading on Monday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 100000 shares changing hands. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Trading Up 50.0 %
The stock has a market capitalization of C$1.99 million, a PE ratio of -1.50 and a beta of 0.05. The company’s 50 day moving average price is C$0.02 and its two-hundred day moving average price is C$0.02. The company has a debt-to-equity ratio of 138.88, a current ratio of 0.09 and a quick ratio of 0.46.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Further Reading
- Five stocks we like better than Aequus Pharmaceuticals
- There Are Different Types of Stock To Invest In
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- How to Effectively Use the MarketBeat Ratings Screener
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- What is the S&P/TSX Index?
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
